BYDUREON (exenatide), antidiabetic

Insufficient clinical benefit to justify reimbursement for type 2 diabetes in combination with basal insulin with or without metformin

• BYDUREON now has MA in combination with a basal insulin for type 2 diabetes patients having failed to achieve adequate glycaemic control.

• Its efficacy on HbA1c variation has only been compared versus placebo, in combination with insulin glargine ± metformin, eventhough a comparison versus a clinically relevant comparator was feasible and all other GLP1 analogues have been compared to an active comparator.

• The effect size of BYDUREON versus placebo appears to be modest.

• There is no evidence of a reduction in insulin use with the addition of BYDUREON.